Change search
ReferencesLink to record
Permanent link

Direct link
Replacement of acetate with citrate in dialysis fluid: a randomized clinical trial of short term safety and fluid biocompatibility
Gambro Lundia AB, Sweden .
Skåne University Hospital, Sweden .
Gambro Lundia AB, Sweden .
Gambro Lundia AB, Sweden .
Show others and affiliations
2013 (English)In: BMC Nephrology, ISSN 1471-2369, Vol. 14, no 216Article in journal (Refereed) Published
Abstract [en]


The majority of bicarbonate based dialysis fluids are acidified with acetate. Citrate, a well known anticoagulant and antioxidant, has been suggested as a biocompatible alternative. The objective of this study was to evaluate short term safety and biocompatibility of a citrate containing acetate-free dialysis fluid.


Twenty four (24) patients on maintenance dialysis three times per week, 13 on on-line hemodiafiltration (HDF) and 11 on hemodialysis (HD), were randomly assigned to start with either citrate dialysis fluid (1 mM citrate, 1.5 mM calcium) or control fluid (3 mM acetate, 1.5 mM calcium) in an open-labeled cross-over trial (6 + 6 weeks with 8 treatments wash-out in between). Twenty (20) patients, 11 on HDF and 9 on HD were included in the analyses. Main objective was short term safety assessed by acid–base status, plasma ionized calcium and parathyroid hormone (PTH). In addition, biocompatibility was assessed by markers of inflammation (pentraxin 3 (PTX-3), CRP, IL-6, TNF-α and IL-1β) and thrombogenicity (activated partial thromboplastin time (APTT) and visual clotting scores).


No differences dependent on randomization order or treatment mode (HD vs. HDF) were detected. Citrate in the dialysis fluid reduced the intra-dialytic shift in pH (+0.04 week 6 vs. +0.06 week 0, p = 0.046) and base excess (+3.9 mM week 6 vs. +5.6 mM week 0, p = 0.006) over the study period. Using the same calcium concentration (1.5 mM), citrate dialysis fluid resulted in lower post-dialysis plasma ionized calcium level (1.10 mM vs. 1.27 mM for control, p < 0.0001) and higher post-dialysis PTH level (28.8 pM vs. 14.7 pM for control, p < 0.0001) while pre-dialysis levels were unaffected. Citrate reduced intra-dialytic induction of PTX-3 (+1.1 ng/ml vs. +1.4 ng/ml for control, p = 0.04) but had no effect on other markers of inflammation or oxidative stress. Citrate reduced visual clotting in the arterial air chamber during HDF (1.0 vs. 1.8 for control, p = 0.03) and caused an intra-dialytic increase in APTT (+6.8 s, p = 0.003) without affecting post-dialysis values compared to control.


During this small short term study citrate dialysis fluid was apparently safe to use in HD and on-line HDF treatments. Indications of reduced treatment-induced inflammation and thrombogenicity suggest citrate as a biocompatible alternative to acetate in dialysis fluid. However, the results need to be confirmed in long term studies.

Place, publisher, year, edition, pages
BioMed Central , 2013. Vol. 14, no 216
National Category
Engineering and Technology
URN: urn:nbn:se:liu:diva-102723DOI: 10.1186/1471-2369-14-216ISI: 000327480800001OAI: diva2:681157

Funding Agencies|Gambro Lundia AB||

Available from: 2013-12-19 Created: 2013-12-19 Last updated: 2014-02-28

Open Access in DiVA

fulltext(408 kB)375 downloads
File information
File name FULLTEXT01.pdfFile size 408 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Search in DiVA

By author/editor
Segelmark, Marten
By organisation
Division of Drug ResearchFaculty of Health SciencesDepartment of Nephrology
In the same journal
BMC Nephrology
Engineering and Technology

Search outside of DiVA

GoogleGoogle Scholar
Total: 375 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 70 hits
ReferencesLink to record
Permanent link

Direct link